Evidence map›Paper›PMID 40131130›Full record

ArticleCA: a cancer journal for clinicians

Averted lung cancer deaths due to reductions in cigarette smoking in the United States, 1970-2022.

Farhad Islami, Nigar Nargis, Qinran Liu, Priti Bandi, Rebecca L Siegel, Parichoy Pal Choudhury, Neal D Freedman, Kenneth E Warner, Ahmedin Jemal

Abstract read
In one paragraph

Article in CA: a cancer journal for clinicians. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Farhad IslamiSurveillance and Health Equity Science, American Cancer Society, Atlanta, Georgia, USA.ORCID https://orcid.org/0000-0002-7357-5994
Nigar NargisSurveillance and Health Equity Science, American Cancer Society, Atlanta, Georgia, USA.
Qinran LiuSurveillance and Health Equity Science, American Cancer Society, Atlanta, Georgia, USA.
Priti BandiSurveillance and Health Equity Science, American Cancer Society, Atlanta, Georgia, USA.
Rebecca L SiegelSurveillance and Health Equity Science, American Cancer Society, Atlanta, Georgia, USA.ORCID https://orcid.org/0000-0001-5247-8522
Parichoy Pal ChoudhurySurveillance and Health Equity Science, American Cancer Society, Atlanta, Georgia, USA.
Neal D FreedmanDivision of Cancer Control and Population Sciences, National Cancer Institute, Rockville, Maryland, USA.
Kenneth E WarnerDepartment of Health Management and Policy, School of Public Health, University of Michigan, Ann Arbor, Michigan, USA.
Ahmedin JemalSurveillance and Health Equity Science, American Cancer Society, Atlanta, Georgia, USA.

Funding

American Cancer Society
6 · The paper itself

Abstract

Lung cancer mortality rates in the United States have declined steeply in recent decades, largely because of substantial reductions in smoking prevalence, as approximately 85% of lung cancer deaths are attributable to cigarette smoking. In this study, the authors estimate the number of averted lung cancer deaths and corresponding person-years of life gained during 1970-2022 as a measure of progress in cancer prevention through tobacco control. By using the 1970-2022 National Center for Health Statistics mortality data (with national coverage), the authors calculated the expected number of deaths for each year, age, sex, race, and age group based on the expected lung cancer death rate multiplied by the population at risk in that group. The number of averted lung cancer deaths were calculated by subtracting the observed number of deaths from the expected number in each group. Person-years of life gained were estimated as a measure of avoided premature mortality based on the average additional years a person would have lived if they had not died from lung cancer. The authors estimated that 3,856,240 lung cancer deaths (2,246,610 in men, 1,609,630 in women) were averted, and 76,275,550 person-years of life (40,277,690 in men, 35,997,860 in women) were gained during 1970-2022, with an average of 19.8 person-years of life gained (17.9 in men, 22.4 in women) per averted death. The number of averted lung cancer deaths accounted for 51.4% of the estimated declines in overall cancer deaths and was substantially greater in men (60.1%) than in women (42.7%). By race, this proportion was 53.6% in the White population (62.8% in men, 44.6% in women) and 40.0% in the Black population (44.4% in men, 34.7% in women). The substantial estimated numbers of averted lung cancer deaths and person-years of life gained highlight the remarkable effect of progress against smoking on reducing premature mortality from lung cancer.

Indexed as

Cigarette SmokingLung NeoplasmsSmokingAdolescentAdultAgedFemaleHumansMaleMiddle AgedMortality, PrematurePrevalenceUnited StatesYoung Adultcigarette smokinglung cancermortalitypreventionrisk factor

Identifiers

PMID40131130
PMCPMC12061630

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.